Evidence map›Paper›PMID 28507937›Full record

ArticleAdvanced pharmaceutical bulletin2017

The Utilization of RNA Silencing Technology to Mitigate the Voriconazole Resistance of Aspergillus Flavus; Lipofectamine-Based Delivery.

Sanam Nami, Behzad Baradaran, Behzad Mansoori, Parivash Kordbacheh, Sasan Rezaie, Mehraban Falahati, Leila Mohamed Khosroshahi, Mahin Safara, Farideh Zaini

Open access · diamondAbstract read
In one paragraph

Article in Advanced pharmaceutical bulletin, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.6field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 17 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Disruption of theRNA (New York, N.Y.) · 2023
    Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Sanam NamiDepartment of Medical Mycology and Parasitology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.
Behzad BaradaranImmunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Behzad MansooriImmunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Parivash KordbachehDepartment of Medical Mycology and Parasitology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.
Sasan RezaieDepartment of Medical Mycology and Parasitology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.
Mehraban FalahatiDepartment of Medical Mycology and Parasitology, Faculty of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Leila Mohamed KhosroshahiDepartment of Immunology, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran.
Mahin SafaraDepartment of Medical Mycology and Parasitology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.
Farideh ZainiDepartment of Medical Mycology and Parasitology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.
Tehran University of Medical Sciences · IRTabriz University of Medical Sciences · IRIran University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Aspergillus flavusCyp51a geneLipofectamineMDR1 geneRNA silencingVoriconazole

Identifiers

PMID28507937
PMCPMC5426734
OpenAlexW2605693703

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.